Everest Medicines appoints Rogers Yongqing Luo as new CEO

China-based Everest Medicines, a biopharmaceutical company focused on developing and commercialising transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, has appointed Rogers Yongqing

Luo as Chief Executive Officer (CEO) of the company, effective immediately. Luo will also serve as an Executive Director on Everest’s Board of Directors. Luo brings to Everest more than 25 years of experience in the healthcare industry with an extensive leadership track record across clinical development, regulatory affairs and commercialization. Previously, Luo served as President and General Manager, Greater China at Brii Biosciences and CEO of TSB Therapeutics where he spearheaded the rapid registration approval, GMP certification and successful commercialisation of the amubarvimab/ romlusevimab combination, the first COVID-19 neutralising antibody treatment in China.